Cancer stem cells: A metastasizing menace!

Cancer Medicine

Volumn 5, Issue 4, 2016, Pages 649-655

  Bandhavkar, Saurabh ^a  

^a KEM HOSPITAL   (India)

Author keywords

Cancer stem cells; Drug resistance; Signaling pathways; Therapeutic potential

Indexed keywords

ALDEHYDE DEHYDROGENASE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CABOZANTINIB; CELL MARKER; CISPLATIN; DIETHYLAMINOBENZALDEHYDE; DOCETAXEL; FLUOROURACIL; GEMCITABINE; METFORMIN; MICRORNA; NOTCH RECEPTOR; PROTEIN P53; RETINOIC ACID; SALINOMYCIN; SONIC HEDGEHOG PROTEIN; SURVIVIN; UNCLASSIFIED DRUG; VORINOSTAT; WNT PROTEIN; BIOLOGICAL MARKER;

ALDEFLUOR ASSAY; APOPTOSIS; CANCER RESISTANCE; CANCER STEM CELL; CANCER THERAPY; CELL ASSAY; CELL DIFFERENTIATION; CELL ISOLATION; CELL TRANSPLANTATION; DRUG MECHANISM; DRUG SENSITIVITY; DRUG TARGETING; ENZYME ACTIVITY; GENE EXPRESSION; GENETIC MANIPULATION; HOECHST DYE EXCLUSION ASSAY; HUMAN; NONHUMAN; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; SPHERE FORMING ASSAY; ANIMAL; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOLOGY; PHENOTYPE;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOMARKERS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASTIC STEM CELLS; PHENOTYPE; SIGNAL TRANSDUCTION;

EID: 84981763580     PISSN: None     EISSN: 20457634     Source Type: Journal    
DOI: 10.1002/cam4.629     Document Type: Review

References (42)

1. Wu, X., H. Chen, and X. Wang . 2012. Can lung cancer stem cells be targeted for therapies?. Cancer Treat. Rev. 38:580-588.
2. Clarke, M. F. 2005. Self-renewal and solid-tumor stem cells. Biol. Blood Marrow Transplant. 11:14-16.
3. Clarke, M. F., J. E. Dick, P. B. Dirks, C. J. Eaves, C. H. Jamieson, D. L. Jones, et al. 2006. Cancer stem cells-perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res. 66:9339-9344.
4. Dick, J. E. 2008. Stem cell concepts renew cancer research. Blood 112:4793-4807.
5. Han, L., S. Shi, T. Gong, Z. Zang, and X. Sun . 2013. Cancer stem cells: therapeutic implications and perspectives in cancer therapy. Sci. Direct 3:65-75.
6. Kumar, D., S. Shankar, and R. K. Srivastava . 2014. Understanding the biological functions and therapeutic potentials of stem cells and cancer stem cells: where are we?. J. Cancer Stem Cell Res. 2:e1002.
7. Li, L., L. Borodyansky, and Y. Yang . 2009. Genomic instability en route to and from cancer stem cells. Cell Cycle 8:1000-1002.
8. Hamaï, A., P. Codogno, and M. Mehrpour . 2014. Cancer stem cells and autophagy: facts and perspectives. J. Cancer Stem Cell Res. 2:e1005.
9. Atena, M., A. Mohammad Reza, and G. Mehran . 2014. A review on the biology of cancer stem cells. Sci. Res. 4:83-89.
10. Paul Medema J. 2013. Cancer stem cells: the challenges ahead. Nat. Cell Biol. 15:338-344. doi:10.1038/ncb2717
11. Qiu, X., Z. Wang, Y. Li, Y. Miao, Y. Ren, and Y Lua . 2012. Characterization of sphere-forming cells with stem-like properties from the small cell lung cancer cell line H446. Cancer Lett. 323:161-170.
12. Pastrana, Erika, Violeta Silva-Vargas, and Fiona Doetsch . 2011. Eyes wide open: a critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 8:486-498.
13. Kim, M. P., J. B. Fleming, H. Wang, J. L. Abbruzzese, W. Choi, S. Kopetz, et al. 2011. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma. PLoS ONE 6:e20636.
14. Ucar, D., C. R. Cogle, J. R. Zucali, B. Ostmark, E. W. Scott, R. Zori, et al. 2009. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem. Biol. Interact. 178:48-55.
15. Priyanka Vaz, A., M. P. Ponnusamy, P. Seshacharyulu, and S. K. Batra . 2014. A concise review on the current understanding of pancreatic cancer stem cells. J. Cancer Stem Cell Res. 2:e1004.
16. Van den Broeck, A., H. Vankelecom, D. W. Van, L. Gremeaux, J. Wouters, and J. Allemeersch, et al. 2013. Human pancreatic cancer contains a side population expressing cancer stem cell-associated and prognostic genes. PLoS ONE 8:e73968.
17. Purton, L. E., and D. T. Scadden . 2007. Limiting Factors in murine hematopoietic stem cell assays. Cell Stem Cell 1:263.
18. Bentwich, I., A. Avniel, Y. Karov, R. Aharonov, S. Gilad, O. Barad, et al. 2005. Identification of hundreds of conserved and nonconserved human microRNAs. Nat. Genet. 37:766-770.
19. Iliopoulos, D., H. A. Hirsch, and K. Struhl . 2009. An epigenetic switch involving NF-kappaB, Lin28, Let-7 MicroRNA, and IL6 links inflammation to cell transformation. Cell 139:693-706.
20. Calin, G. A., C. D. Dumitru, M. Shimizu, R. Bichi, S. Zupo, E. Noch, et al. 2002. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. USA 99:15524-15529.
21. Michael, M. Z., S. M. O'Connor, van Holst Pellekaan N. G., G. P. Young, and R. J. James . 2003. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 1:882-891.
22. Croce, C. M. 2009. Causes and consequences of microRNA dysregulation in cancer. Nat. Rev. Genet. 10:704-714.
23. Hebrok, M. 2003. Hedgehog signaling in pancreas development. Mech. Dev. 120:45-57.
24. Wang, Z. W., Y. W. Li, S. Banerjee, and F. H. Sarkar . 2008. Exploitation of the notch signaling pathway as a novel target for cancer therapy. Anticancer Res. 28:3621-3630.
25. Pannuti, A., K. Foreman, P. Rizzo, C. Osipo, and T. Golde . 2010. Targeting notch to target cancer stem cells. Clini. Cancer Res. 16:3141-3152.
26. Klaus, A., and W. Birchmeier 2008. Wnt signalling and its impact on development and cancer. Nat. Rev. Cancer 8:387-398.
27. Teng, Y., X. Wang, Y. Wang, and D. Ma . 2010. Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem. Biophys. Res. Commun. 392:373-379.
28. Zhou, J., J. Wulfkuhle, H. Zhang, P. Gu, Y. Yang, J. Deng, et al. 2007. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. USA 104:16158-16163.
29. Singh, A. K., R. K. Arya, S. Maheshwari, A. Singh, S. Meena, P. Pandey, et al. 2014. Tumor heterogeneity and cancer stem cell paradigm: updates in concept, controversies and clinical relevance. Int. J. Cancer 136:1991-2000.
30. Singh, B.N., J. Fu, R. K. Srivastava, and S. Shankar . 2011. Hedgehog signaling antagonist GDC-0449 (Vismodegib) inhibits pancreatic cancer stem cell characteristics: molecular mechanisms. PLoS ONE 6:27-30.
31. Fan, X., L. Khaki, T.S. Zhu, M.E. Soules, C.E. Talsma, N. Gul, et al. 2010. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells 28:5-16.
32. Kondratyev, M., A. Kreso, R. M. Hallett, A. Girgis-Gabardo, M. E. Barcelon, D. Llieva, et al. 2012. Gamma-secretase inhibitors target tumor-initiating cells in a mouse model of ERBB2 breast cancer. Oncogene 31:93-103.
33. Wang, W., C. Zhao, D. Jou, J. Lu, C. Zhang, L. Lin, et al. 2013. Ursolic acid inhibits the growth of colon cancer-initiating cells by targeting STAT3. Anticancer Res. 33:4279-4284.
34. Lonardo, E., M. Cioffi, P. Sancho, Y. Sanchez-Ripoll, S. M. Trabulo, J. Dorado, et al. 2013. Metformin targets the metabolic achilles heel of human pancreatic cancer stem cells. PLoS ONE 8:e76518.
35. Naujokat, C., and R. Steinhart . 2012. Salinomycin as a drug for targeting human cancer stem cells. J. Biomed. Biotechnol. 2012:9506-9558.
36. Hage, C., V. Rausch, N. Giese, T. Giese, F. Schönsiegel, S. Labsch, et al. 2013. The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer. Cell Death Dis. 4:e627.
37. + human breast cancer cells. Breast Cancer Res. Treat. 133:75-87.
38. Lou, H., and M. Dean . 2007. Targeted therapy for cancer stem cells: the patched pathway and ABC transporters. Oncogene 26:1357-1360.
39. Nozawa, H., T. Tadakuma, T. Ono, M. Sato, S. Hiroi, K. Masumoto, et al. 2006. Small interfering RNA targeting epidermal growth factor receptor enhances chemosensitivity to cisplatin, 5-fluorouracil and docetaxel in head and neck squamous cell carcinoma. Cancer Sci. 97: 1115-1124.
40. Boeckler, F. M., A. C. Joerger, G. Jaggi, T. J. Rutherford, D. B. Veprintsev, and A. R. Fersht . 2008. Targeted rescue of a destabilised mutant of p53 by an in silico screened drug. Proc. Natl. Acad. Sci. USA 105:10360-10365.
41. Sharma, H., S. Sen, L. M. L. Mraiggiò, and N. Singh . 2005. Antisense-mediated downregulation of antiapoptotic proteins induces apoptosis and sensitises head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol. Ther. 4:720-727.
42. Butler, L. M., X. Zhou, W.S. Xu, H.I. Scher, R.A. Rifkind, P.A. Marks, et al. 2002. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. PNAS 99:11700-11705.